Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Benralizumab and mepolizumab,"Severe eosinophilic asthma, second biologic line",Benralizumab and mepolizumab (Fasenra and Nucala),Options for investment,Community and Hospital,Respiratory System and Allergies
